David Rubin, MD, on the GALAXI 2 and 3 Trials of Guselkumab in Crohn's Disease

Dr Rubin reviews the results of phase 3 trials of guselkumab for treatment of Crohn's disease among patients who are bionaive, bioexposed, and biointolerant or who failed to respond to biologics.